Product Images Clopidogrel
View Photos of Packaging, Labels & Appearance
- pdp - 68071 2813 9
- Figure - clopidogrel fig1
- Figure - clopidogrel fig2
- Figure - clopidogrel fig3
- Figure - clopidogrel fig4
- Figure - clopidogrel fig5
- Figure - clopidogrel fig6
- Change relative to clopidogrel bisulfate administered alone - clopidogrel fig8
- Figure - clopidogrel fig9
- clopidogrel-str - clopidogrel str
Product Label Images
The following 10 images provide visual information about the product associated with Clopidogrel NDC 68071-2813 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 2813 9
This is a description of NuCare Pharmaceuticals' product with the name DRoaM. DRoaM is a 75mg film-coated tablet containing Clopidogrel Bisulfate USP. Each tablet has 97.875mg of Clopidogrel Bisulfate USP, equivalent to 75mg of Clopidogrel base. The tablets come in bottles of 90 tablets, with a unique serial number and an expiration date of 00-00. The manufacturer's label contains a list of all ingredients. Customers are advised to store the product within temperatures of 68-77°F and should keep it out of the reach of children. Customers who need more information are directed to contact the manufacturer or call 1-800-FDA-1088.*
Figure - clopidogrel fig1
This is a graph displaying the cumulative event rate for fatal or non-fatal vascular events for both Aspirin and Clopidogrel Bisulfate over a period of 36 months of follow-up. The graph shows that there is a statistically significant difference between the two treatments (p=0.045).*
Figure - clopidogrel fig2
This is a table displaying the cumulative event rate for cardiovascular death, myocardial infarction, and stroke over a period of follow-up months. The data compares the use of placebo (with aspirin) and clopidogrel bisulfate (with aspirin) and shows a statistically significant difference in the event rate between the two treatments. No other information or context is available.*
Figure - clopidogrel fig3
Figure - clopidogrel fig4
This text is a report of clinical trial results comparing the effects of a placebo versus a medication called Clopidogrel. The report includes the percentage of deaths before the first discharge in both groups, as well as the number of deaths and proportional risk reduction in the Clopidogrel group. It also indicates the days since randomization when the measurements were taken (up to 28 days).*
Figure - clopidogrel fig5
This text appears to be a brief summary of the results of a clinical trial testing the effectiveness of Clopidogrel in reducing the risk of death, re-infarction, or stroke in patients before their first discharge. The trial included a group treated with a placebo and a group treated with Clopidogrel, with the latter group experiencing a 9% reduction in risk of these events (compared to the placebo group). There is also a reference to randomization.*
Figure - clopidogrel fig6
Change relative to clopidogrel bisulfate administered alone - clopidogrel fig8
Figure - clopidogrel fig9
This appears to be a table or chart of some kind with information related to stroke, PAD (peripheral artery disease), and two drugs: Clopidogrel and Aspirin. The table includes four years of data (06-09) and another set of years (0, 11-13) with unclear context. The final column includes a hazard ratio with a 95% confidence interval. It is difficult to provide more context or a specific use for this data without additional information.*
clopidogrel-str - clopidogrel str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
